A 12-Month, Randomized, Open-Label, Phase IIA Study Evaluating the Safety and Efficacy of Siplizumab in Combination with Belatacept and MPA Compared to Standard of Care Immunosuppression in de novo Renal Transplant Recipients (ASCEND)

Project: Clinical Trial

Project Details

StatusActive
Effective start/end date3/22/24 → …